Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), ProQR (PRQR) and Spyre Therapeutics ...

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), ProQR (PRQR) and Spyre Therapeutics (SYRE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and Healthequity (HQY). Amgen (AMGN) ...

Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Healthequity (HQY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN) and Healthequity (HQY). Read More on AMGN: Amgen pri...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Healthequity (HQY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pro Medicus Limited (PMCUF) and Amgen (AMGN) with bu...

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and Amgen (AMGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and Alector (ALEC) with bullish sentime...

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Analysts fell to the sidelines weighing in on Amgen (AMGN) and Airsculpt Technologies (AIRS) with neutral ratings, indicating that the experts are ...

Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT), Pharvaris (PHVS) and Amgen (AMGN) w...

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The new Amgen Inc. rollover study, officially titled “An Open-label, Rollove...

Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Amgen, with a price target of $390.00. Bansal covers the Health...

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has reported a key update on its Phase 3 ROCKET-Outpost st...

Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GIL...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The Phase 1/1b study “A Phase 1/1b Study Evaluating the Safety, Tolerability...

Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.34% in Friday’s pre-market trading. Investor...

Invesco QQQ Trust ETF (QQQ) Daily Update, 3/13/2026

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen yesterday and set a price target of $335.00. The company’s shares closed yesterd...

Bernstein Sticks to Their Hold Rating for Amgen (AMGN)

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), fell 0.32% in Thursday’s pre-market trading as rising...

Invesco QQQ Trust ETF (QQQ) Daily Update, 3/12/2026

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.02% in Wednesday’s pre-market trading...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$355.60	+1.66%	2.94M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$355.60	+1.7%	2.94M
3
4
5
6

AMGN

AMGN

No Data Available

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel